|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,410.00 JPY | -1.41% |
|
-2.13% | +5.48% |
| 01:54am | Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge | MT |
| 09:18pm | Innovent Biologics Closes Takeda Partnership, Issues New Shares | MT |
| Capitalization | 7,066B 45.66B 39.15B 36.61B 34.19B 63.67B 4,101B 68.97B 430B 166B 1,938B 171B 168B | P/E ratio 2026 * |
40.2x | P/E ratio 2027 * | 24.1x |
|---|---|---|---|---|---|
| Enterprise value | 11,009B 71.14B 61B 57.05B 53.28B 99.2B 6,390B 107B 669B 258B 3,019B 267B 261B | EV / Sales 2026 * |
2.44x | EV / Sales 2027 * | 2.36x |
| Free-Float |
99.61% | Yield 2026 * |
4.47% | Yield 2027 * | 4.55% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | -1.41% | ||
| 1 week | -2.13% | ||
| Current month | -2.13% | ||
| 1 month | +5.96% | ||
| 3 months | -3.59% | ||
| 6 months | +3.18% | ||
| Current year | +5.48% |
| 1 week | 4,400 |  | 4,509 |
| 1 month | 4,148 | | 4,549 |
| Current year | 3,916 | | 4,670 |
| 1 year | 3,916 | | 4,670 |
| 3 years | 3,852 | | 4,873 |
| 5 years | 2,993 | | 4,873 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 59 | 2015-03-31 |
Mwana Lugogo
CMP | Compliance Officer | 55 | 2011-12-31 |
| Chief Tech/Sci/R&D Officer | 70 | 2015-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Christophe Weber
BRD | Director/Board Member | 59 | 2014-05-31 |
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
| Director/Board Member | 73 | 2016-05-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 24.44% | 27 M€ | +4.39% | - |
| 5% | 476 M€ | +22.24% | - |
| 3.8% | 2,393 M€ | +18.68% | - |
| 3.43% | 4 M€ | -30.99% | - |
| 3.26% | 120 M€ | +18.76% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.41% | -2.13% | +6.57% | +11.50% | 45.66B | |
| +1.01% | -8.14% | +22.25% | +170.70% | 908B | |
| +0.10% | -2.45% | +34.57% | +13.19% | 488B | |
| -0.18% | +0.46% | +29.61% | +39.75% | 404B | |
| +0.97% | +1.98% | +22.32% | +1.28% | 331B | |
| +0.90% | -2.72% | +28.03% | +20.73% | 280B | |
| +0.70% | +3.12% | +19.21% | +25.57% | 256B | |
| +0.58% | -3.57% | -0.47% | -8.32% | 250B | |
| +2.80% | -1.23% | -59.39% | -30.47% | 212B | |
| -0.56% | -1.28% | +22.25% | +19.14% | 183B | |
| Average | +0.54% | -1.80% | +12.49% | +26.31% | 335.86B | |
| Weighted average by Cap. | +0.73% | -3.05% | +18.12% | +55.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4,507B 29.12B 24.97B 23.35B 21.81B 40.61B 2,616B 43.99B 274B 106B 1,236B 109B 107B | 4,545B 29.37B 25.18B 23.55B 22B 40.96B 2,638B 44.37B 276B 107B 1,247B 110B 108B |
| Net income | 178B 1.15B 985M 922M 861M 1.6B 103B 1.74B 10.81B 4.17B 48.78B 4.31B 4.22B | 294B 1.9B 1.63B 1.53B 1.42B 2.65B 171B 2.87B 17.9B 6.91B 80.75B 7.14B 6.99B |
| Net Debt | 3,944B 25.48B 21.85B 20.44B 19.09B 35.54B 2,289B 38.49B 240B 92.51B 1,082B 95.64B 93.6B | 3,640B 23.52B 20.17B 18.86B 17.61B 32.8B 2,113B 35.53B 221B 85.38B 998B 88.27B 86.39B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 4,410.00 ¥ | -1.41% | 3,004,400 |
| 25-12-04 | 4,473.00 ¥ | +0.43% | 3,370,300 |
| 25-12-03 | 4,454.00 ¥ | -0.40% | 3,408,700 |
| 25-12-02 | 4,472.00 ¥ | -0.82% | 3,913,800 |
| 25-12-01 | 4,509.00 ¥ | +0.07% | 3,739,600 |
Delayed Quote Japan Exchange, December 05, 2025 at 01:30 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition